Related Experiment Videos
Development of gene therapy for hemoglobin disorders
Arthur W Nienhuis1, Hideki Hanawa, Nobukuni Sawai
1Division of Experimental Hematology, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. arthur.nienhuis@stjude.org
Annals of the New York Academy of Sciences
|June 12, 2003
Summary
Gene therapy using lentiviral vectors shows promise for treating hemoglobin disorders like beta-thalassemia and sickle cell anemia by correcting stem cells. A novel drug-selection system enhances gene-corrected cell amplification for potential therapeutic applications.
Area of Science:
- Hematology
- Molecular Biology
- Gene Therapy
Background:
- Hemoglobin disorders, including severe beta-thalassemia and sickle cell anemia, are significant global health burdens.
- Current gene therapy strategies focus on correcting stem cells for sustained therapeutic effects.
Purpose of the Study:
- To evaluate lentiviral vectors for gene transfer into stem cells to correct hemoglobin disorders.
- To develop a drug-selection system for amplifying gene-corrected stem cells without myeloablation.
Main Methods:
- Utilized lentiviral vectors to deliver a gamma-globin gene into murine stem cells.
- Developed a drug-selection system employing a mutant methylguanine-methyltransferase for selective stem cell amplification.
- Assessed phenotypic correction of the thalassemia phenotype in treated murine models.
Main Results:
- Demonstrated successful gene transfer of a gamma-globin gene into murine stem cells using lentiviral vectors.
- Achieved phenotypic correction of the thalassemia phenotype in treated murine models.
- Established a drug-selection system enabling amplification of gene-corrected stem cells, even without myeloablative conditioning.
Conclusions:
- Lentiviral vectors are effective for gene transfer into stem cells for hemoglobin disorders.
- The developed drug-selection system offers a novel approach for enhancing gene therapy efficacy.
- These preclinical findings support the advancement of gene therapy for severe hemoglobin disorders.